ReAlta Life Sciences, Inc. Report issue

For profit Phase 2
Founded: Norfolk VA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04574869
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, ReAlta Life Sciences, Inc. | ReAlta Life Sciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

rls-0071 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Lung Injury (Phase 1)

Pneumonia (Phase 1)

Respiratory Distress Syndrome (Phase 1)

Respiratory Insufficiency (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1